SAFETY DATA SHEET



1. Identification

Product identifier Evista®

Other means of identification

VF0366, UC4810, TA4166, VF0338, VF0316, TA4466, TA4165, TA4164, VF0317, VF0297, **Item Code**

VF0298, TA4012, ND1002, TA4013, VF0374, SA1006, BO2059, UC4165, ZD4165

LY139481 Hydrochloride * Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl[4-[2 **Synonyms**

-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride

LY Number LY139481 Pharmaceutical Recommended use **Recommended restrictions** None known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Company name Eli Lilly and Company Lilly Corporate Center **Address** Indianapolis, IN 46285

United States

Phone: +1-317-276-2000 **Telephone**

E-mail lilly msds@lilly.com

CHEMTREC: +1-800-424-9300 **Emergency phone number**

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Carcinogenicity Category 2

> Reproductive toxicity Category 1A

OSHA defined hazards Not classified.

Label elements



Signal word Danger

Hazard statement

Suspected of causing cancer. H351

May damage fertility or the unborn child. H360

Precautionary statement

Prevention

Obtain special instructions before use. P201

Use personal protective equipment as required. P281

Do not handle until all safety precautions have been read and understood. P202

Response

IF exposed or concerned: Get medical advice/attention. P308 + P313

Storage Not available. Disposal Not available. Hazard(s) not otherwise None known.

classified (HNOC)

Supplemental information None.

3. Composition/information on ingredients

Mixtures

Material name: Evista® SDS US

Chemical name	Common name and synonyms	CAS number	%
Raloxifene Hydrochloride	[6-hydroxy-2-(4-hydroxyphenyl)-1-benzot hiophen-3-yl][4-(2-piperidin-1-ylethoxy)ph enyl]methanone hydrochloride Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]th ien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl] -, hydrochloride Benzothiophene	82640-04-8	10 - 65
Composition comments	Remaining components of this product are non-hazardous and/or are present at concentrations		

4. First-aid measures

Inhalation Remove to fresh air. If breathing stops, provide artificial respiration. Get medical attention

immediately.

below reportable levels.

Skin contact Wash off immediately with plenty of water. Continue to rinse for at least 15 minutes. Immediately

take off all contaminated clothing. Get medical attention if irritation develops and persists.

Eye contact In case of eye contact, remove contact lens and rinse immediately with plenty of water, also under

the eyelids, for at least 15 minutes. Get medical attention.

Ingestion Immediately give large quantities of water to drink. Never give anything by mouth to a victim who is

unconscious or is having convulsions. Call a physician immediately.

Most important symptoms/effects, acute and

symptoms/effects, acute and delayed

Exposure to raloxifene hydrochloride resulted in skin rash/redness. Raloxifene hydrochloride is a Selective Estrogen Receptor Modulator (SERM) and is highly potent. Reproductive effects in females and developmental effects are associated with compounds in this pharmacological class, including raloxifene hydrochloride.

General information Capsules or tablets are not considered hazardous under normal handling procedures. Capsules

and tablets are intended for human consumption under guidance of a physician.

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing media

Carbon dioxide, dry chemical or water.

None known.

Specific hazards arising from

the chemical

During a fire, irritating and highly toxic gases may be generated by thermal decomposition or

combustion. Chloride.

Special protective equipment and precautions for firefighters

Wear self-contained breathing apparatus and protective clothing.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures Wear suitable protective clothing, gloves and eye/face protection. See Section 8 of the SDS for Personal Protective Equipment.

Methods and materials for containment and cleaning up Environmental precautions

Do not sweep. Collect spill using a vacuum cleaner with a HEPA filter. If vacuum is not available,

lightly mist/wet material and remove by mopping or wet wiping. Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Avoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling. See Section 8 of the SDS for Personal Protective Equipment.

Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

8. Exposure controls/personal protection

Occupational exposure limits

Bio

Lilly (LEG) Components	Туре	Value	
Raloxifene Hydrochloride (CAS 82640-04-8)	Excursion Limit	130 ug/m3	
	TWA (12hrs)	5 ug/m3	
	TWA (8hrs)	8 ug/m3	
ological limit values	No biological exposure limits noted for the ingredient(s).		

Material name: Evista® sps us

Appropriate engineering

controls

Open handling is not recommended. Use appropriate control measures such as fume hood, ventilated enclosure, isolator (i.e. glove bag/glove box) and/or closed transfers to maintain airborne

levels below occupational exposure level (OEL).

Individual protection measures, such as personal protective equipment

Eye/face protection Safety glasses with side shields recommended. If splash potential or dusty operations, wear

goggles/faceshield.

Skin protection

Hand protection Chemical resistant gloves.

Other Chemical-resistant gloves and impermeable body covering to minimize skin contact.

Respiratory protection Respirator selection must be based on known or anticipated exposure levels, the hazards of the

product and the safe working limits of the respirator. If the applicable occupational exposure level (OEL) is anticipated to be exceeded, wear an approved respirator with sufficient protection factor to control exposure below the OEL. If material is handled in a fume hood or ventilated enclosure,

consider using redundant respiratory protection.

Thermal hazards Not available.

General hygiene considerations

Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material. Raloxifene Hydrochloride is an active pharmaceutical ingredient with a therapeutic dose in humans at or below 1 mg/day.

9. Physical and chemical properties

Appearance

Physical state Solid.
Form Tablet.
Color Light yellow
Odor Odorless

Odor threshold

pH

No data available.

Melting point/freezing point

No data available.

No data available.

No data available.

range

Flash point Not applicable.

Evaporation rate No data available.

Flammability (solid, gas) No test data available.

Upper/lower flammability or explosive limits

Flammability limit - lower

vei

No data available.

Flammability limit - upper

(%)

(%)

No data available.

Explosive limit - lower (%) No data available.

Explosive limit - upper (%) No data available.

Vapor pressure No data available.

Vapor density No data available.

Relative density No data available.

Solubility(ies)

Solubility (water) Insoluble

Partition coefficient No data available.

(n-octanol/water)

Auto-ignition temperature

No data available.

Pecomposition temperature

No data available.

No data available.

Other information

DensityNo data available. **Explosive properties**Not explosive.

Material name: Evista® sps us

Oxidizing properties The substance or mixture is not classified as oxidizing.

Percent volatile No data available. VOC No data available.

10. Stability and reactivity

Reactivity Not water reactive.

Chemical stability Material is stable under normal conditions. Possibility of hazardous Hazardous polymerization does not occur.

reactions

Conditions to avoid None known.

Strong oxidizing substances. Incompatible materials

Hazardous decomposition

products

During a fire, irritating and highly toxic gases may be generated by thermal decomposition or

combustion. Chloride.

11. Toxicological information

Information on toxicological effects

Acute toxicity Based on available data, the classification criteria are not met.

Components **Test Results**

Raloxifene Hydrochloride (CAS 82640-04-8)

Acute **Dermal**

LD Rabbit > 200 mg/kg

Inhalation

LC50 Monkey > 27 mg/m3, 8 hr

Oral

LD Rat > 5000 mg/kg

Rabbit: Slight irritation. (Raloxifene hydrochloride) Skin corrosion/irritation

Based on available data, the classification criteria are not met.

Serious eye damage/eye

Rabbit: Slight irritation. (Raloxifene hydrochloride)

Based on available data, the classification criteria are not met. irritation

Respiratory or skin sensitization

Respiratory sensitization Due to lack of data the classification is not possible.

Skin sensitization Did not cause sensitization on laboratory animals. (Raloxifene hydrochloride)

Based on available data, the classification criteria are not met.

In vitro and in vivo tests did not show mutagenic effects. (Raloxifene hydrochloride) Germ cell mutagenicity

Based on available data, the classification criteria are not met.

Carcinogenicity Suspected of causing cancer. Increased incidences of ovarian, testicular, and prostatic tumors

were reported in long-term studies in rodents. These effects were attributed to dose-dependent

hormonal pharmacology. (Raloxifene hydrochloride)

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

No pregnancies occurred when male and female rats were given daily doses of 5 mg/kg prior to Reproductive toxicity

and during mating. In female rats, disrupted estrous cycles and inhibited ovulation (all reversible), and delayed and disrupted embryo implantation resulting in prolonged gestation and reduced litter size were reported. Developmental effects reported included decreased fetal weight and delayed skeletal development, growth retardation, malformations of the heart, edema, and hydrocephaly in offspring. In male rats, daily doses up to 100 mg/kg for at least 2 weeks did not affect sperm production/quality or reproductive performance. Decreased prostate weights and a single case of

aspermatogenesis were observed in dogs given 30 mg/kg for 6-months. No significant

observations in sperm count/motility and morphology were observed in humans during a 3-month

clinical trial when given daily doses of 120 mg. (Raloxifene hydrochloride)

Specific target organ toxicity single exposure

Due to lack of data the classification is not possible.

Material name: Evista®

Specific target organ toxicity - repeated exposure

No significant target organ toxicity reported. (Raloxifene hydrochloride)

Based on available data, the classification criteria are not met.

Aspiration hazard

No aspiration toxicity classification

Further information

Exposure to raloxifene hydrochloride resulted in skin rash/redness. Raloxifene hydrochloride is a Selective Estrogen Receptor Modulator (SERM) and is highly potent. Reproductive effects in females and developmental effects are associated with compounds in this pharmacological class,

including raloxifene hydrochloride.

12. Ecological information

Ecotoxicity

Components		Species	Test Results
Raloxifene Hydrochlor	ride (CAS 82640-04-8)		
Acute			
	EC50	Selenastrum capricornutum (new name Pseudokirchnerella subca	1.21 mg/l (average specific growth rate)
	IC50		> 1000 mg/l (Fungus)
			> 1000 mg/l (Mold)
			> 1000 mg/l (Bacteria, soil)
			> 1000 mg/l (Bacteria, n-fixing)
Aquatic			
Acute			
Algae	IC50	Blue-green algae (Spirulina platensis)	875 mg/l
Crustacea	EC50	Daphnia magna	2.43 mg/l
	NOEC	Daphnia magna	0.165 mg/l
Fish	LC50	Oncorhynchus mykiss	1.45 mg/l, 96 hr

A LAEG is the maximum allowable concentration at the point of application that is expected to result in no appreciable risk to populations of aquatic and terrestrial organisms, or to human health.

LILLY AQUATIC EXPOSURE GUIDELINES:

Raloxifene Hydrochloride

Acute LAEG (at the edge of the acute mixing zone):
Chronic LAEG (at the edge of the chronic mixing zone):

0.01 µg/l 0.01 µg/l

Drinking water LAEG (at the point where surface water is taken for drinking water):

3.5 µg/l

Persistence and degradability Hydrolysis half-life (days): 1001, 410, 90 (pH 5, 7, 9)

Sewage sludge degradation half-life (0.47 g/L total suspended solids): 7.17 hours

Aerobic biodegradation half-life (0.03 g/L total suspended solids): 37 days

Bioaccumulative potential log Kow: < 4.

Partition coefficient n-octanol / water (log Kow)

Raloxifene Hydrochloride 2.71 (pH 5) 3.12 (pH 7)

3.19 (pH 9)

Mobility in soil No data available.

Other adverse effects Not available.

13. Disposal considerations

Disposal instructions Dispose of contents/container in accordance with local/regional/national/international regulations.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

UN number UN3077

UN proper shipping name Transport hazard class(es) Environmentally hazardous substances, solid, n.o.s. (Raloxifene Hydrochloride)

Class 9 Subsidiary risk -

Material name: Evista® SDS US

Packing group III
Environmental hazards Yes
ERG Code 9L

Special precautions for user Not available.

Other information

Passenger and cargo

aircraft

Allowed with restrictions.

Cargo aircraft only

Allowed with restrictions.

IMDG

UN number UN3077

UN proper shipping name Transport hazard class(es) Environmentally hazardous substances, solid, n.o.s. (Raloxifene Hydrochloride)

Class 9
Subsidiary risk Packing group III

Environmental hazards

Marine pollutant Yes EmS F-A, S-F


Special precautions for user Not available.

Transport in bulk according to Not available.

Annex II of MARPOL 73/78 and

the IBC Code

IATA; IMDG



Marine pollutant



15. Regulatory information

US federal regulations This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication

Standard, 29 CFR 1910.1200.

One or more components are not listed on TSCA.

CERCLA/SARA Hazardous Substances - Not applicable.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

Material name: Evista® sps us

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Classified hazard Carcinogenicity Reproductive toxicity categories

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material **US** state regulations

is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or region Inventory name On inventory (yes/no)* Canada Domestic Substances List (DSL) No Canada Non-Domestic Substances List (NDSL) No United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory No

16. Other information, including date of preparation or last revision

Issue date 12-08-2014 **Revision date** 02-27-2019

Version # 05

LEG: Lilly Exposure Guideline. List of abbreviations

TWA: Time Weighted Average

Disclaimer As of the date of issuance, we are providing available information relevant to the handling of this

material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature

which may accompany the finished product.

For additional information contact:

Eli Lilly and Company **Hazard Communication** +1-317-651-9533

Material name: Evista® 7/7

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).